Nektar Therapeutics (NKTR) |
|
0.7029 0.067 (10.52%)
|
03-31 16:00 |
|
Open: |
0.6561 |
Pre. Close: |
0.636 |
|
High:
|
0.7067 |
Low:
|
0.62 |
|
Volume:
|
16,103,211 |
Market Cap:
|
133(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:20:47 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 1.42  One year: 1.86 |
| Support: |
Support1: 0.6 Support2: 0.5 |
| Resistance: |
Resistance1: 1.21 Resistance2: 1.6 |
| Pivot: |
0.88 |
| Moving Average: |
MA(5): 0.7 MA(20): 0.98
MA(100): 2.39 MA(250): 3.32 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 7.8 %D(3): 4.9 |
| RSI: |
RSI(14): 24.6 |
| 52-week: |
High: 6.26 Low: 0.6 |
| Average Vol(K): |
3-Month: 3,136 (K) 10-Days: 7,379 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NKTR ] has closed above bottom band by 26.6%. Bollinger Bands are 28.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.71 - 0.71 |
0.71 - 0.71 |
|
Low:
|
0.61 - 0.62 |
0.62 - 0.62 |
|
Close:
|
0.7 - 0.7 |
0.7 - 0.71 |
|
Company Description |
|
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California. |
Headline News |
Thu, 30 Mar 2023
Why Is Nektar (NKTR) Down 51.9% Since Last Earnings Report? - Nasdaq
Wed, 29 Mar 2023
Nektar Therapeutics slips, PacWest Bancorp gains on S&P index ... - Seeking Alpha
Fri, 24 Mar 2023
Nektar (NKTR) Upgraded to Buy: Here's Why - Nasdaq
Tue, 21 Mar 2023
Nektar Therapeutics (NASDAQ:NKTR) Given Consensus ... - MarketBeat
Tue, 14 Mar 2023
Sage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left ... - Nasdaq
Mon, 13 Mar 2023
Nektar Therapeutics Has No Exposure to Silicon Valley Bank By ... - Investing.com India
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
188 (M) |
| Shares Float |
186 (M) |
|
% Held by Insiders
|
1.3 (%) |
|
% Held by Institutions
|
89.4 (%) |
|
Shares Short
|
9,930 (K) |
|
Shares Short P.Month
|
9,000 (K) |
Stock Financials |
|
EPS
|
-2.5 |
|
EPS Est Next Qtl
|
-0.35 |
|
EPS Est This Year
|
-0.99 |
|
EPS Est Next Year
|
-1.11 |
|
Book Value (p.s.)
|
5.98 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-328.6 |
|
Return on Assets (ttm)
|
-19 |
|
Return on Equity (ttm)
|
-74.9 |
|
Qtrly Rev. Growth
|
-5.2 |
|
Gross Profit (p.s.)
|
0.4 |
|
Sales Per Share
|
0.5 |
|
EBITDA (p.s.)
|
-1.6 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-398 (M) |
|
Levered Free Cash Flow
|
-189 (M) |
Stock Valuations |
|
PE Ratio
|
-0.29 |
|
PEG Ratio
|
0.1 |
|
Price to Book value
|
0.11 |
|
Price to Sales
|
1.39 |
|
Price to Cash Flow
|
-0.34 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
